Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jacobio Pharmaceuticals
Biotech
AstraZeneca fronts $100M for Jacobio's pan-KRAS inhibitor
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing a clinical-stage, multitarget asset from China’s Jacobio Pharma.
James Waldron
Dec 22, 2025 4:31am
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Aug 30, 2024 9:12am
Jacobio's KRAS data tee up safety-focused lung cancer pitch
May 1, 2024 7:01am
AbbVie sends Chinese biotech's SHP2 pact back to port
Jul 5, 2023 10:50am
HebeCell lands $53M to make a splash in busy CAR-NK space
Sep 1, 2021 8:35am
AbbVie pens cancer pact with U.S.-China biotech Jacobio
Jun 1, 2020 8:30am
